Transplantasyon öncesi fibrinojen ve D-dimer düzeylerinin otolog kök hücre transplantasyonu sonuçlarına etkisi

Year 2025, Volume: 8 Issue: 4, 621 - 628, 30.07.2025

Neslihan Mandacı Şanlı , Edanur Dilara Mandacı

https://doi.org/10.32322/jhsm.1711682

An Erratum to this article was published on September 16, 2025. https://dergipark.org.tr/en/pub/jhsm/issue/94685/1784678

Abstract

Amaç: Bu çalışmada, hematolojik maligniteler bağlamında otolog hematopoetik kök hücre transplantasyonu (auto-HSCT) uygulanan hastalarda serum D-dimer ve fibrinojen düzeylerinin prognoz üzerindeki etkisinin değerlendirilmesi amaçlanmıştır.

Yöntemler: Bu retrospektif çalışmaya 2010 ile 2024 yılları arasında auto-HSCT uygulanan 152 yetişkin hasta dahil edilmiştir. Transplantasyon öncesi D-dimer ve fibrinojen düzeyleri kaydedilmiştir. Sağkalım analizleri Kaplan–Meier eğrileri ve Cox regresyon yöntemleriyle yapılmıştır. ROC analizi ile eşik değerler belirlenmiştir.

Bulgular: D-dimer ve fibrinojen için sırasıyla >860 ng/mL ve >448 mg/dL eşik değerleri, artmış nüks ve mortalite oranları ile istatistiksel olarak anlamlı bulunmuştur. D-dimer ve fibrinojen düzeyleri mortalite (HR: 96.74 ve 5.478) ve nüks (HR: 24.254 ve 6.921) açısından bağımsız prediktörler olarak belirlenmiştir. Bu biyobelirteçlerin yüksek seviyeleri, beş yıllık genel sağkalım oranlarını anlamlı şekilde azaltmıştır.

Sonuç: Yüksek D-dimer ve fibrinojen düzeylerine sahip auto-HSCT hastalarının prognozu olumsuzdur ve transplantasyon sonuçları kötüdür. Bu biyobelirteçlerin ucuz ve erişilebilir olması, transplantasyon öncesi risk sınıflaması yapılarak hedefe yönelik tedavi planlamasında kolaylık sağlar.

Keywords

Otolog kök hücre transplantasyonu , D-dimer , Fibrinojen , Prognoz , Hematolojik malignite

The impact of pre-transplant fibrinogen and D-dimer levels on transplantation outcomes in autologous stem cell transplantation

An Erratum to this article was published on September 16, 2025. https://dergipark.org.tr/en/pub/jhsm/issue/94685/1784678

Abstract

Aims: Determine how serum D-dimer and fibrinogen levels affect the prognosis of patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT) within the context of underlying hematologic malignancies.
Methods: This retrospective study included 152 adult patients who received auto-HSCT between 2010 and 2024. D-dimer and fibrinogen levels were documented prior to the transplant. Survival analyses were performed with Kaplan-Meier curves and Cox regression methods. ROC analysis provided cut-off values.
Results: The D-dimer and fibrinogen cut-off levels of >860 ng/ml and >448 mg/dl, respectively, were statistically significant with increased rates of relapse and mortality. Mortality was independently predicted by D-dimer and fibrinogen (HR: 96.74 and 5.478) and relapse (HR: 24.254 and 6.921). Increased levels of the markers significantly reduced the five-year overall survival.
Conclusion: Auto-HSCT patients with elevated D-dimer and fibrinogen have unfavorable prognoses and poor outcomes. The inexpensive nature of these biomarkers allows greater ease in establishing risk stratification for targeted pre-transplant planning.

Keywords

Autologous stem cell transplantation , D-dimer , fibrinogen , prognosis , hematologic malignancy

Ethical Statement

This study was approved by the Erciyes University Clinical Research Ethics Committee (Approval No: 2025/31, Date: 22.01.2025).

Supporting Institution

The authors received no financial support for the research, authorship, and/or publication of this article.

References

• Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44. doi:10.1038/s41408-019-0205-9
• Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217-226. doi:10.1007/s11899-017-0382-1
• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. doi:10. 1182/blood.2020008824
• Linkins LA, Takach Lapner S. Review of D-dimer testing: good, bad, and ugly. Int J Lab Hematol. 2017;39(Suppl 1):98-103. doi:10.1111/ijlh.12665
• Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-2420. doi:10.1016/j.jacc.2017.09.024
• Franchini M, Focosi D, Pezzo MP, Mannucci PM. How we manage a high D-dimer. Haematologica. 2023;109(4):1035-1045. doi:10.3324/haematol.2023.283966
• Schafer K, Goldschmidt E, Oostra D, Fish J, Russell T, Lurie F. The clinical significance of ultra-high D-dimer levels. J Vasc Surg Venous Lymphat Disord. 2022;10(1):8-13. doi:10.1016/j.jvsv.2021.06.011
• Ozen M, Yilmaz A, Cakmak V, et al. D-dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021;40:55-59. doi: 10.1016/j.ajem.2020.12.023
• He X, Yao F, Chen J, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11(1):1830. doi:10.1038/s41598-021-81300-w
• Fan BE, Lippi G, Favaloro EJ. D-dimer levels for the exclusion of pulmonary embolism: making sense of international guideline recommendations. J Thromb Haemost. 2024;22(3):604-608. doi:10.1016/j.jtha.2023.12.015
• Cosmi B, Legnani C, Libra A, Palareti G. D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications. Pol Arch Intern Med. 2023;133(11):16604. doi:10.20452/pamw.16604
• Mandacı Şanlı N, Keklik M, Ünal A. Pretransplant serum fibrinogen level may be a predictive marker on chronic graft-versus-host disease (cGVHD) in patients having undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). Int J Hematol Oncol. 2022;32(1):1-8.
• Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007;5(Suppl 1):246-254. doi:10.1111/j.1538-7836.2007. 02497.x
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. doi:10.1056/nejmoa1703327
• Go SI, Lee MJ, Lee WS, et al. D-dimer can serve as a prognostic and predictive biomarker for metastatic gastric cancer treated by chemotherapy. Medicine (Baltimore). 2015;94(30):e951. doi:10.1097/MD. 0000000000000951
• Bi XW, Wang L, Zhang WW, et al. High pretreatment D-dimer levels correlate with adverse clinical features and predict poor survival in patients with natural killer/T-cell lymphoma. PLoS One. 2016;11(3): e0152842. doi:10.1371/journal.pone.0152842
• Batschauer AP, Figueiredo CP, Bueno EC, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010;21(6):1267-1272. doi:10.1093/annonc/mdp474
• Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005;3(8):1618-1627. doi:10.1111/j.1538-7836.2005.01416.x
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-444. doi:10.1038/nature072 05
• Kleber M, Ihorst G, Terhorst M, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1(9):e35-38. doi:10.1038/bcj.2011.34
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-Specific Comorbidity Index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919. doi:10.1182/blood-2005-05-2004
• Fukumoto K, Taniguchi T, Usami N, et al. Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer. Surg Today. 2015;45(1):63-67. doi: 10.1007/s00595-014-0894-4
• Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20(3):170-175. doi:10.1097/MBC.0b013e32831bc2de
• Mandacı Şanlı N, Keklik M, Ünal A. Role of uric acid levels as a prognostic indicator in allogeneic hematopoietic stem cell transplantation: insights from a single-center study. Cumhuriyet Med J. 2024;46(2):121-128. doi: 10.7197/cmj.1428410